BackBlack Diamond Therapeutics Overview

Black Diamond Therapeutics Receivables

Track Black Diamond Therapeutics's receivables ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer trimmed avg / median

Loading

Black Diamond Therapeutics Receivables History

Loading

Black Diamond Therapeutics vs. peers: Receivables Comparison

Loading

Black Diamond Therapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Black Diamond Therapeutics (BDTX) FAQ

The latest receivables for BDTX is $0 as of June 2026. In the prior-year period, the figure was $0. Investors often review this figure alongside Black Diamond Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, BDTX's receivables moved from $0 to $0. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Black Diamond Therapeutics's operating scale or balance-sheet position.

A receivables figure of $0 for BDTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BDTX's receivables ($0), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Black Diamond Therapeutics's receivables against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.